Lu D, Ellegast J, Ross K, Malone C, Lin S, Mabe N
Nat Cell Biol. 2023; 25(2):285-297.
PMID: 36658220
PMC: 9928584.
DOI: 10.1038/s41556-022-01059-8.
Reppel L, Tsahouridis O, Akulian J, Davis I, Lee H, Fuca G
J Immunother Cancer. 2022; 10(1).
PMID: 35022195
PMC: 8756261.
DOI: 10.1136/jitc-2021-003897.
Qasim S, Sierra L, Shuck R, Kurenbekova L, Patel T, Rajapakshe K
Oncogene. 2021; 40(6):1176-1190.
PMID: 33414491
DOI: 10.1038/s41388-020-01600-9.
Lee M, Kim D, Kim H, Park H, Lee J, Sung K
Cell Prolif. 2019; 52(3):e12577.
PMID: 30724400
PMC: 6536445.
DOI: 10.1111/cpr.12577.
Neviani P, Wise P, Murtadha M, Liu C, Wu C, Jong A
Cancer Res. 2018; 79(6):1151-1164.
PMID: 30541743
PMC: 6428417.
DOI: 10.1158/0008-5472.CAN-18-0779.
Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.
Woodfield S, Guo R, Liu Y, Major A, Hollingsworth E, Indiviglio S
Genes Cancer. 2016; 7(1-2):13-26.
PMID: 27014418
PMC: 4773702.
DOI: 10.18632/genesandcancer.97.
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield S, Zhang L, Scorsone K, Liu Y, Zage P
BMC Cancer. 2016; 16:172.
PMID: 26925841
PMC: 4772351.
DOI: 10.1186/s12885-016-2199-z.
JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells.
Kuo Y, Liu Y, Adebayo B, Shih P, Lee W, Wang L
PLoS One. 2015; 10(5):e0125343.
PMID: 25951238
PMC: 4423965.
DOI: 10.1371/journal.pone.0125343.
PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.
Saulnier Sholler G, Currier E, Dutta A, Slavik M, Illenye S, Mendonca M
J Cancer Ther Res. 2014; 2:21.
PMID: 25520806
PMC: 4266584.
DOI: 10.7243/2049-7962-2-21.
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A, Liu D, Tian G, Courtney A, Wei J, Marinova E
Blood. 2014; 124(18):2824-33.
PMID: 25049283
PMC: 4215313.
DOI: 10.1182/blood-2013-11-541235.
The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
Scorsone K, Zhang L, Woodfield S, Hicks J, Zage P
Invest New Drugs. 2014; 32(5):815-24.
PMID: 24832869
DOI: 10.1007/s10637-014-0107-4.
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
Farooqi A, Dagg R, Choi L, Shay J, Reynolds C, Lau L
J Neurooncol. 2014; 119(1):17-26.
PMID: 24792489
DOI: 10.1007/s11060-014-1456-8.
Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
Veschi V, Petroni M, Cardinali B, Dominici C, Screpanti I, Frati L
PLoS One. 2012; 7(11):e49139.
PMID: 23152863
PMC: 3494673.
DOI: 10.1371/journal.pone.0049139.
Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL.
Kim H, Lee M, Kim D, Jo H, Lee S, Chueh H
Cell Biol Int Rep (2010). 2012; 19(1):e00017.
PMID: 23124518
PMC: 3475444.
DOI: 10.1042/CBR20110008.
UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.
Zage P, Sirisaengtaksin N, Liu Y, Gireud M, Brown B, Palla S
Cancer. 2012; 119(4):915-23.
PMID: 22990745
PMC: 3527637.
DOI: 10.1002/cncr.27785.
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.
Liu D, Song L, Wei J, Courtney A, Gao X, Marinova E
J Clin Invest. 2012; 122(6):2221-33.
PMID: 22565311
PMC: 3366399.
DOI: 10.1172/JCI59535.
Notch pathway activation induces neuroblastoma tumor cell growth arrest.
Zage P, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay P
Pediatr Blood Cancer. 2011; 58(5):682-9.
PMID: 21744479
PMC: 3264695.
DOI: 10.1002/pbc.23202.
The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.
Levy A, Zage P, Akers L, Ghisoli M, Chen Z, Fang W
Invest New Drugs. 2010; 30(1):191-9.
PMID: 20890785
PMC: 4831635.
DOI: 10.1007/s10637-010-9551-y.
Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.
Das C, Zage P, Taylor P, Aguilera D, Wolff J, Lee D
Eur J Cancer. 2010; 46(15):2771-80.
PMID: 20886683
PMC: 3025305.
DOI: 10.1016/j.ejca.2010.05.010.
Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.
Richards K, Zweidler-McKay P, Van Roy N, Speleman F, Trevino J, Zage P
Cancer. 2010; 116(13):3233-43.
PMID: 20564646
PMC: 2923448.
DOI: 10.1002/cncr.25073.
